The Pharmacy Times® Retail Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to retail, community, and independent pharmacists.
September 28th 2024
Adults with underlying medical conditions, resulting in an increased risk of respiratory syncytial virus disease are more likely to be cost-effective than general age-based strategies.
EMPA-REG Trial: Implications for Type 2 Diabetes Treatment, CV Risk Reduction
November 14th 2017In this clip, Eliot A. Brinton, MD, FAHA, FNLA, president of the Utah Lipid Center, discusses how the EMPA-REG trial is a huge step forward for health care providers being able to treat patients with type 2 diabetes with medications that also reduce cardiovascular risk.
Read More
National Association of Specialty Pharmacy Voices Support for #APharmacistIs Campaign
November 10th 2017Pharmacy Times and Specialty Pharmacy Times recently announced the launch of a new social media campaign to spread awareness about the work pharmacists do to improve their patients' lives.
Read More
Scientific Community Continues Searching for Answers to Cannabinoid Questions
November 8th 2017State and local marijuana laws continue to evolve toward legalization much faster than the scientific community can collect the data to help society weigh the health, safety, and ethical ramifications of these new laws.
Read More
CANVAS Trial: Canagliflozin Linked with Improved Renal Outcomes
November 7th 2017Canagliflozin (Invokana, Janssen) improved renal outcomes and demonstrated potential renal protective effects, according to additional analyses from the CANVAS clinical trial presented at the American Society of Nephrology Kidney Week 2017 Annual Meeting.
Read More
Biologics, Triple Therapy Effective Option After Failed Initial Methotrexate Treatment
November 7th 2017Patients with rheumatoid arthritis (RA) who took biologics or triple therapy had a longer fail time than patients who took methotrexate oral monotherapy, suggesting that these treatments may be a good follow-up to failed first-line methotrexate treatment.
Read More
FDA Approves First Treatment for Rare Blood Cancer
November 6th 2017Officials with the FDA have extended the approval of vemurafenib (Zelboraf, Genentech) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare blood cancer, making it the first approved treatment for ECD.
Read More